Home Health & Wellness Sublingual Treatment Improves Stroke Outcomes

Sublingual Treatment Improves Stroke Outcomes

Reading Time: 2 minutes

Stroke is one of the leading causes of disability worldwide, with millions suffering from its debilitating consequences each year. But a new clinical trial offers new hope. The recent study, conducted across 33 centres in China, focuses on the efficacy of a novel treatment for acute ischemic stroke (AIS): sublingual edaravone dexborneol.

This treatment combines two potent ingredients, edaravone and dexborneol, known for their antioxidant and anti-inflammatory properties. The randomised clinical trial aimed to evaluate the effectiveness of this new sublingual formulation in improving the functional outcomes of stroke patients over 90 days.

The findings were published in JAMA Neurology.

The study enrolled 914 patients with AIS, who were promptly treated within 48 hours of symptom onset. Participants were randomly assigned to receive either the sublingual edaravone dexborneol or a placebo, maintaining the double-blind standard. This large-scale, placebo-controlled, multicenter phase 3 trial stretched from June 2021 to August 2022, with patients closely monitored for three months post-treatment.

The results revealed that 64.4% of patients in the treatment group showed a significant improvement in their functional outcomes by the 90th day, compared to 54.7% in the placebo group. This marked improvement was supported by a statistically significant risk difference of 9.70% between the two groups.

Interestingly, the study found no significant increase in adverse events among those treated with the new drug compared to the placebo, indicating that the treatment is not only effective but also safe for wide-scale use.

One of the critical innovations of this study is the sublingual delivery method. This approach allows the medication to be absorbed directly into the blood through tissues under the tongue, bypassing the digestive system and promoting quicker response times – a crucial factor in stroke treatment where every minute counts.

The promising results of this trial suggest that sublingual edaravone dexborneol could revolutionize the treatment of acute ischemic stroke, especially in scenarios where intravenous access is not available or delayed. It offers a practical solution that can be administered promptly and effectively, potentially reducing the time to treatment, which is often critical in stroke recovery.

The study’s implications extend beyond immediate stroke recovery, suggesting potential for reducing long-term disabilities associated with stroke. This could significantly ease the social and economic burdens associated with long-term care and rehabilitation for stroke survivors.

© Copyright 2014–2034 Psychreg Ltd